Healthcare
•3753 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3753)
| Company | Market Cap | Price |
|---|---|---|
|
BTMD
biote Corp.
Vertical pellet therapy and related implantable products can be categorized under Medical Devices & Biometrics.
|
$114.70M |
$2.32
-2.93%
|
|
VTVT
vTv Therapeutics Inc.
Cadisegliatin is an oral, small-molecule therapeutic developed by the company for Type 1 Diabetes, directly matching the 'Oral Small Molecule Therapeutics' category.
|
$113.69M |
$36.15
-2.97%
|
|
SERA
Sera Prognostics, Inc.
Direct Laboratory Testing & Advisory Services provided by SERA for the PreTRM test and related diagnostic offerings.
|
$113.42M |
$3.02
+1.34%
|
|
CAMP
CAMP4 Therapeutics Corporation
Direct product category: oligonucleotide therapeutics (RNA Actuating Platform) using ASOs to upregulate gene expression.
|
$113.31M |
$5.66
-2.08%
|
|
IPSC
Century Therapeutics, Inc.
Directly develops iPSC-derived cell therapies (CAR-iT, CAR-iNK, Allo-Evasion-enabled products) and related platforms.
|
$112.31M |
$1.76
+35.38%
|
|
EHTH
eHealth, Inc.
eHealth's core business is to facilitate enrollment in health insurance products (Medicare and other plans).
|
$111.84M |
$3.67
-4.56%
|
|
RPTX
Repare Therapeutics Inc.
Core company focus is oncology therapeutics with a synthetic lethality approach (Biotech - Oncology).
|
$110.83M |
$2.59
+0.78%
|
|
FBIO
Fortress Biotech, Inc.
Fortress Biotech directly encompasses oncology-focused biotech through its portfolio (e.g., Mustang Bio) and related assets, aligning with Biotech - Oncology.
|
$110.69M |
$3.73
+7.04%
|
|
ULBI
Ultralife Corporation
Products targeted at medical use (X5 medical care products, wearable power) place Ultralife in Medical Devices & Biometrics.
|
$110.35M |
$6.68
-5.11%
|
|
MBOT
Microbot Medical Inc.
LIBERTY functions as a vascular/interventional device for endovascular surgery, aligning with Vascular Intervention Devices.
|
$109.77M |
$2.27
-6.02%
|
|
PYXS
Pyxis Oncology, Inc.
Pyxis Oncology is a biotechnology company focused on oncology therapeutics, with MICVO as its lead asset in cancer.
|
$109.15M |
$1.76
-4.35%
|
|
MGNX
MacroGenics, Inc.
Pipeline includes antibody-drug conjugates (MGC026, MGC028, vobra duo) using a TOP1i payload.
|
$108.71M |
$1.72
|
|
ARTV
Artiva Biotherapeutics, Inc.
AlloNK AB-101 is an allogeneic NK cell therapy platform, constituting Artiva's core product line.
|
$107.96M |
$4.38
-1.91%
|
|
SLSN
Solesence, Inc. Common Stock
Solésence operates as a contract development and manufacturing organization (CDMO) for beauty products, matching Contract Manufacturing Organizations.
|
$107.84M |
$1.54
-1.28%
|
|
CGTX
Cognition Therapeutics, Inc.
CT1812 (zervimesine) is an orally delivered small-molecule therapeutic, the core product of the company.
|
$107.27M |
$1.47
+6.16%
|
|
SEER
Seer, Inc.
SP100 instrument and related proteomics hardware qualify as Diagnostic Equipment.
|
$106.48M |
$1.89
-1.31%
|
|
AGEN
Agenus Inc.
Agenus' core focus is oncology with immunotherapy approaches (BOT/BAL) in MSS CRC, supporting Biotech - Oncology.
|
$106.43M |
$3.35
-8.83%
|
|
UNCY
Unicycive Therapeutics, Inc.
Lead programs Oxylanthanum Carbonate (OLC) and UNI-494 are oral small-molecule therapeutics targeting kidney disease and hyperphosphatemia/acute kidney injury.
|
$106.15M |
$6.21
+3.41%
|
|
ICAD
iCAD, Inc.
iCAD operates in the Medical Imaging domain, providing imaging software for breast health diagnostics.
|
$105.91M |
$3.87
|
|
ACOG
Alpha Cognition Inc. Common Stock
ZUNVEYL is Alpha Cognition's lead therapeutic targeting Alzheimer's disease.
|
$105.05M |
$6.50
+5.18%
|
|
ANIX
Anixa Biosciences, Inc.
CER-T CAR-T therapy is a direct cell therapy product focused on oncology.
|
$105.00M |
$3.21
-0.47%
|
|
HLVX
HilleVax, Inc.
Direct vaccine development activity with norovirus vaccine candidates (HIL-216.00) and existing vaccine focus.
|
$104.79M |
$2.09
|
|
RCEL
AVITA Medical, Inc.
RECELL System and Cohealyx/PermeaDerm are wound care devices used for wound closure and healing.
|
$103.81M |
$3.91
+13.01%
|
|
GUTS
Fractyl Health, Inc. Common Stock
Revita DMR System is a medical device used in outpatient endoscopic/metabolic procedures, representing a direct product Fractyl Health develops and sells.
|
$103.60M |
$2.02
-2.18%
|
|
GNLX
Genelux Corporation
Genelux focuses on oncology-focused viral immunotherapies, categorized under Biotech - Oncology.
|
$103.50M |
$2.75
+7.42%
|
|
XGN
Exagen Inc.
Exagen provides diagnostic testing services and operates lab facilities for autoimmune diagnostics.
|
$103.20M |
$4.69
-2.90%
|
|
PRLD
Prelude Therapeutics Incorporated
Prelude is a clinical-stage biotech focused on oncology, with an advanced pipeline targeting SMARCA2/SMARCA4 and related cancer pathways.
|
$102.45M |
$1.81
-15.58%
|
|
CRBP
Corbus Pharmaceuticals Holdings, Inc.
Corbus's pipeline is focused on oncology assets (CRB-701 and CRB-601) representing biotech oncology products.
|
$101.96M |
$8.36
+2.33%
|
|
MREO
Mereo BioPharma Group plc
Mereo's core focus is developing therapeutics for rare diseases, fitting the Biotech - Rare Diseases category.
|
$101.82M |
$0.64
-4.64%
|
|
NCSM
NCS Multistage Holdings, Inc.
Tracer diagnostics capabilities and studies are a key service offering for reservoir and well performance analysis.
|
$101.41M |
$40.66
+3.59%
|
|
RANI
Rani Therapeutics Holdings, Inc.
RT-111 and RT-105 include ustekinumab and adalimumab biosimilars, fitting the biosimilars category.
|
$99.90M |
$1.41
+1.08%
|
Showing page 25 of 38 (3753 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
